HPV Detection Not Predictive of Cervical Precancer

Share this content:
HPV Detection Not Predictive of Cervical Precancer
HPV Detection Not Predictive of Cervical Precancer

(HealthDay News) — Detection of human papillomavirus (HPV) 6, 11, 42 or combination infections does not identify increased 3-year risk of cervical precancer, according to a study published in the January issue of Obstetrics & Gynecology.

Philip E. Castle, PhD, MPH, from the Albert Einstein College of Medicine in New York City, and colleagues used data from the New Mexico Human Papillomavirus Pap Registry for a stratified sample of 59,644 residual cervical cytology specimens that underwent HPV genotyping from a population of 379,000 cytology specimens. The 3-year cumulative incidence of cervical intraepithelial neoplasia grade 2 or more severe (CIN 2+) and grade 3 or more severe (CIN 3+) was assessed after detection of 581 single or multiple infections of HPV 6, 11, or 42.

The researchers found that there was a 0.8% overall prevalence of a single infection of HPV 6, 11, or 42. After 581 HPV 6, 11, 42, or combinations infections, the 3-year risk of CIN 2+ and CIN 3+ were 0.4% and 0.0%, respectively. In comparison, after a negative HPV result (27,522 cytologic results), the 3-year risks of CIN 2+ and CIN 3+ were 0.2% and 0.1%, respectively.

"Testing for HPV 6, 11, 42, or combinations of those types should be discontinued because it has no proven benefit to patients," the authors wrote.

Roche Molecular Systems provided the Genotyping Test and equipment to automate the HPV genotyping assays. Two authors disclosed financial ties to pharmaceutical and biotechnology companies, including Roche.

References

  1. Castle PE, Hunt WC, Langsfeld E, et al. Three-Year Risk of Cervical Precancer and Cancer After the Detection of Low-Risk Human Papillomavirus Genotypes Targeted by a Commercial Test. Obstet Gynecol. 2014;doi:10.1097/AOG.0000000000000013.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters